


The top selling biologics market is projected to be worth USD 156 billion by 2030, claims Roots Analysis

The top selling biologics market is projected to be worth USD 156 billion by 2030, claims Roots Analysis


LONDON, ENGLAND, UNITED KINGDOM, October 11, 2021 /EINPresswire.com/ -- Owing to the numerous benefits offered by biologics, this drug class has become an integral part of the overall pharmaceutical industry, having captured a significant market share over the past couple of decades

<u>Roots Analysis</u> has announced the addition of the "<u>Top Selling Biologics</u> <u>Market</u>, 2021 – 2030" report to its list of offerings.

Over the years, around 200 biologics have been approved for the treatment of various disease indications in the US and Europe. In 2020, 18 new biologics received approval by the USFDA. Despite their complex and cost Example highlights



Top Selling Biologics Market - RootsAnaysis



intensive manufacturing protocols, biopharmaceuticals (once approved) are considered to be highly profitable assets. In the recent past, many biological interventions have achieved blockbuster status (in some cases, registering revenues worth over USD 4 billion a year); prominent examples include (arranged in decreasing order of 2020 revenues) Humira[®], Keytruda[®], Stelara[®], Opdivo[®], Avastin[®], Trulicity[®], Enbrel[®], Ocrevus[™] and Rituxan[®].

To order this 320+ page report, which features 190+ figures and 195+ tables, please visit this <u>https://www.rootsanalysis.com/reports/top-selling-biologics-market.html</u>

Key Market Insights

More than 65 top selling biologics (revenues equal to or above USD 500 million in 2020) are currently available in the market

Majority (54%) of the aforementioned candidates are monoclonal antibodies, followed by hormones (19%) and enzymes (9%). Further, subcutaneous route (50%) emerged as the most preferred route of administration for such therapies, followed by the intravenous route (40%).

More than 50% the developers of top selling biologics are based in North America

The top <u>selling biologics market</u> is currently dominated by the presence of large companies (82%). Additionally, majority of such players were established before the year 2000.

Over 2,450 clinical trials registered for the evaluation of top selling biologics, till Q3 2020

Of the total, 1,892 trials were registered for the evaluation of products targeting oncological Example highlights

The biologics market is presently characterized by a number of blockbuster drugs; in fact, in 2020, a little over 65 such products were responsible for total sales worth over USD 185 billion

|--|--|

			2020 Sales (USD Million)				Available Packaging Formats				
1	HUMIRA	AbbVie	19,832	Monoclonal Antibody	TNF α	Subcutaneous	~	~	×		
5	Nucala 🌶	GlaxoSmithKline	1,215	Monoclonal Antibody	IL-5	Subcutaneous	×	×		×	
11	they	Eli Lilly	2,626	Hormone	IR	Intravenous, Subcutaneous	Packaging Formats and Dose Strengths				
18	PERJETA	Genentech	4,391	Monoclonal Antibody	HER2	Subcutaneous, Infravenous		YTRUDA	4	Contraction Fasenral	
22	RDARZALEX	Janssen Biotech	4,190	Monoclonal Antibody	CD-38	Subcutaneous	E E	tribund)-search	Nucala 尨		
26	SPINRAZA	Biogen	2,052	Gene Therapy	SMN2	Intrathecal	Viala		Vial, Prefiled Syringes,	Prefiled Pans, Prefiled	
29	YERVOILS	Bristol-Myers Squibb	1,682	Monoclonal Antibody	CTLA-4	Intravenous			Autoinjectors	Syringes	
35	Specta	Amgen	2,763	Monoclonal Antibody	RANKL	Intravenous			ä 🖊 🛿		
37	3 IMPINZT	AstraZeneca	2,042	Monoclonal Antibody	PD-L1	Intravenous	50 mg	100 mg/4mL	100 100 100 mg mg/mL mg/mL	30 30 mg/mL mg/mL	
43	Humulin	Eli Lilly	1,260	Hormone	IR	Subcutaneous					
45	CIRANZA	Eli Lilly	1,033	Monoclonal Antibody	VEGF	Intravenous	Q	AVASTIN	taltz	Kadcyla'	
47	Toujeo	Sanofi	1,141	Hormone	IR	Subcutaneous	Vals		Prefiled Syringes,	Vals	
50	Herceptin	Genentech	4,220	Monoclonal Antibody	HER2	Intravenous, Subcutaneous			Autoinjectors		
54	OONAL-0	Merck	630	Hormone	FSH	Subcutaneous					
56	ILARIS	Novartis	873	Monoclonal Antibody	IL-1ß	Subcutaneous	100 mg/ 4	400 mL mg/14mL	80 80 mg/mL mg/mL	100 160 mg mg	
59	Benheste)	GlaxoSmithKline	879	Monoclonal Antibody	BLyS	Intravenous, Subcutaneous					
61	VIMIZIM	Biomarin	544	Enzyme	GALNS	Intravenous	<u> </u>	yophilized Powder	G Solution		
65	GALTYA	Roche	715	Monoclonal Antibody	CD-20	Intravenous	~	×	4		

Allow-values: The Turon Hoose State, HB2, Human Esplematignen that Respects, 20, R. Humin Respects CO. 20, Lower of Efferentian D. 8, RM2, Sunkal Offictor Human 2, CTLA-4. Optional - Information and the analysis of the State Sta

Selling Biologics Market, 2021-2030 - Roots Analysis



disorders, followed by those investigating biologics intended for the treatment of metabolic disorders (122) and autoimmune disorders (98).

Around 250 biosimilars of top selling biologics are currently approved / under development Close to 30% of the aforementioned candidates have already been approved. It is worth mentioning that over 100 biosimilars have received approval in Asia Pacific. Within this region, India and South Korea emerged as key hubs, having granted maximum approvals for biosimilars of top selling biologics (in terms of 2020 revenues).

Monoclonal antibodies are anticipated to capture over 75% of the market share by 2030 Over 40% of the market share is anticipated to be capture by Genentech / Roche and Merck by 2030. It is worth mentioning that as the patents of the currently marketed products have already / are expected to expire towards the end of the forecast period, the market is likely to reach maturity. To request a sample copy / brochure of this report, please visit this <u>https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-sample.html</u> Key Questions Answered

Which biologics are likely to attain the blockbuster status in the foreseen future?
Who are the leading players engaged in the development of top selling biologics?
Which key clinical conditions are presently targeted by top selling biologics?
What are the historical global sales of top selling biologics?
Which are the most commonly adopted product life cycle management strategies by players for their top selling products?
What is the current annual treatment cost associated with top selling biologics?
Which regions have emerged as the key hubs for conducting clinical studies focused on top selling biologics?

IBow has the biosimilars landscape in this market evolved over the past few years?IWhich factors are likely to influence the evolution of this market?

Delow is the current and future market opportunity likely to be distributed across key market segments?

The USD 156 billion (by 2030) financial opportunity associated with the top selling biologics market has been analyzed across the following segments:

Type of Biologic

□Monoclonal Antibodies

- □Ħormones
- Elusion Proteins
- □Enzymes
- Dinterferons

Antibody Fragments

- □**G**ene Therapies
- □**V**accines

Key Developers Genentech / Roche AbbVie Janssen Biotech / Johnson & Johnson Amgen Eli Lilly Bristol Myers Squibb Sanofi Novo Nordisk Regeneron sales@rootsanalysis.com

You may also be interested in the following titles: 1.Novel T-Cell Immunotherapies Market, 2021-2030 2.IIL-based Therapies Market, 2021-2030 3.Non-Hormonal Therapies Market, 2021-2030 4.Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030 5.Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030

Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com

Gaurav Chaudhary Roots Analysis +1 415-800-3415 email us here Visit us on social media: Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/553556227

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.